Myriad Genetics, Inc. (MYGN)
Automate Your Wheel Strategy on MYGN
With Tiblio's Option Bot, you can configure your own wheel strategy including MYGN - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol MYGN
- Rev/Share 9.0952
- Book/Share 7.7123
- PB 0.4979
- Debt/Equity 0.2236
- CurrentRatio 1.9007
- ROIC -0.1149
- MktCap 353961216.0
- FreeCF/Share -0.3917
- PFCF -9.8872
- PE -3.4613
- Debt/Assets 0.1566
- DivYield 0
- ROE -0.1409
- Rating C
- Score 2
- Recommendation Sell
- P/E Score 1
- DCF Score 1
- P/B Score 4
- D/E Score 2
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Downgrade | MYGN | Scotiabank | Sector Outperform | Sector Perform | -- | $6 | May 21, 2025 |
| Downgrade | MYGN | Wolfe Research | Outperform | Peer Perform | -- | -- | May 8, 2025 |
| Downgrade | MYGN | Wells Fargo | Overweight | Equal Weight | -- | $6 | May 7, 2025 |
| Downgrade | MYGN | Guggenheim | Buy | Neutral | -- | -- | April 9, 2025 |
| Upgrade | MYGN | Piper Sandler | Neutral | Overweight | $11.5 | $12.5 | March 12, 2025 |
| Initiation | MYGN | Craig Hallum | -- | Buy | -- | $29 | Feb. 12, 2025 |
| Initiation | MYGN | UBS | -- | Neutral | -- | $18 | Dec. 10, 2024 |
| Downgrade | MYGN | Leerink Partners | Outperform | Market Perform | $30 | $21 | Dec. 9, 2024 |
| Initiation | MYGN | Morgan Stanley | -- | Equal Weight | -- | $32 | Sept. 19, 2024 |
| Initiation | MYGN | Wells Fargo | -- | Overweight | -- | $35 | Aug. 28, 2024 |
News
Myriad Genetics Faces Cost Restructuring As UnitedHealthcare Ends GeneSight Coverage, Appoints New CEO
Published: February 25, 2025 by: Benzinga
Sentiment: Negative
On Monday, in its earnings release, Myriad Genetics Inc. MYGN said Unitedhealth Group Inc's UNH UnitedHealthcare will stop covering multi-gene panel pharmacogenetic testing, including Myriad Genetics' GeneSight test, for its commercial, individual exchange, and certain managed Medicaid plans. This change takes effect in the first half of 2025.
Read More
MYGN Q4 Earnings Meet Estimates, Revenues Rise Y/Y, Stock Down
Published: February 25, 2025 by: Zacks Investment Research
Sentiment: Neutral
Myriad Genetics achieves strong revenue growth in the fourth quarter of 2024.
Read More
Myriad (MYGN) Reports Q4 Earnings: What Key Metrics Have to Say
Published: February 24, 2025 by: Zacks Investment Research
Sentiment: Positive
The headline numbers for Myriad (MYGN) give insight into how the company performed in the quarter ended December 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Read More
Myriad Genetics (MYGN) Meets Q4 Earnings Estimates
Published: February 24, 2025 by: Zacks Investment Research
Sentiment: Positive
Myriad Genetics (MYGN) came out with quarterly earnings of $0.03 per share, in line with the Zacks Consensus Estimate. This compares to earnings of $0.04 per share a year ago.
Read More
About Myriad Genetics, Inc. (MYGN)
- IPO Date 1995-10-06
- Website https://myriad.com
- Industry Medical - Diagnostics & Research
- CEO Samraat S. Raha
- Employees 2700